Aragon Pharmaceuticals Nabs $50M
Aragon Pharmaceuticals has closed a $50 million Series D round, the company announced Thursday. Aragon is developing therapeutics for hormone-driven cancers. venBio led the financing with participation from existing investors Topspin Fund, Aisling Capital, OrbiMed Advisors and The Column Group.
4 October 2012•3 mins read
